Literature DB >> 11036287

Colorectal carcinogenesis based on molecular biology of early colorectal cancer, with special reference to nonpolypoid (superficial) lesions.

T Watanabe1, T Muto.   

Abstract

The multistep genetic model of colorectal carcinogenesis is based on the concept of the adenoma-carcinoma sequence. The adenoma-carcinoma sequence theory has been generally accepted for polypoid early colorectal cancers (ECCs). On the other hand, an increasing number of nonpolypoid (superficial) ECC have been reported. Nonpolypoid (superficial) ECCs show distinct characteristics histologically and genetically, and some claim these lesions may develop by de novo type carcinogenesis. In fact, clinicopathologic studies have shown that most nonpolypoid (superficial) cancers have no adenomatous lesions in the surrounding area. Genetic analyses have also revealed that nonpolypoid (superficial) ECCs show a pattern of genetic alterations different from that of polypoid ECCs. The K-ras mutation rate is lower in nonpolypoid (superficial) ECCs than in polypoid ECCs, but there is no significant difference in the p53 mutation rate between two types of tumor. During the development of ECCs, the K-ras gene seems to determine the macroscopic configuration: whether polypoid or nonpolypoid (superficial). These results suggest that nonpolypoid (superficial) ECCs originate from a pathway different from the conventional genetic pathway that follows the adenoma-carcinoma sequence. However, this does not mean that this new pathway is following de novo type carcinogenesis, because there is a possibility that nonpolypoid (superficial) adenomas, or so-called flat adenomas, develop into nonpolypoid (superficial) ECCs following the adenoma-carcinoma sequence. At the present time, there is still not enough evidence to conclude whether nonpolypoid (superficial) ECC is derived from de novo carcinogenesis or the conventional adenoma-carcinoma sequence. Further analysis, especially concerning APC gene mutation in ECCs, is essential to elucidate the carcinogenesis of nonpolypoid (superficial) ECCs.

Entities:  

Mesh:

Year:  2000        PMID: 11036287     DOI: 10.1007/s002680010149

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  5 in total

1.  Molecular validation of the modified Vienna classification of colorectal tumors.

Authors:  Tamotsu Sugai; Wataru Habano; Noriyuki Uesugi; Yu-Fei Jiao; Shin-ichi Nakamura; Kimihiko Sato; Toshimi Chiba; Motohiro Ishii
Journal:  J Mol Diagn       Date:  2002-11       Impact factor: 5.568

2.  Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma.

Authors:  Shinichi Mukai; Toru Hiyama; Shinji Tanaka; Masaharu Yoshihara; Koji Arihiro; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

3.  Histopathological and genetic differences between polypoid and non-polypoid submucosal colorectal carcinoma.

Authors:  Ichiro Hirata; Fang-Yu Wang; Mitsuyuki Murano; Takuya Inoue; Ken Toshina; Takashi Nishikawa; Kentaro Maemura
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

4.  Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia.

Authors:  Sangkyou Lee; Joon Jeong; Tadeusz Majewski; Steven E Scherer; Mi-Sook Kim; Tomasz Tuziak; Kuang S Tang; Keith Baggerly; Herbert Barton Grossman; Jain-Hua Zhou; Lanlan Shen; Jolanta Bondaruk; Saira S Ahmed; Susmita Samanta; Philippe Spiess; Xifeng Wu; Slawomir Filipek; David McConkey; Menashe Bar-Eli; Jean-Pierre Issa; William F Benedict; Bogdan Czerniak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

5.  Establishment and characterization of a new cell line derived from human colorectal laterally spreading tumor.

Authors:  Xin-Ying Wang; Zhou-Sheng Lai; Chung-Man Yeung; Ji-De Wang; Wen Deng; Hoi-Yee Li; Yu-Jing Han; Hsiang-Fu Kung; Bo Jiang; Marie Chia-mi Lin
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.